ARWRARROWHEAD PHARMACEUTICALS, ...

Nasdaq arrowheadpharma.com


$ 23.61 $ 0.25 (1.07 %)    

Tuesday, 20-Aug-2024 15:59:59 EDT
QQQ $ 480.15 $ -1.01 (-0.21 %)
DIA $ 408.54 $ -0.55 (-0.13 %)
SPY $ 558.65 $ -0.91 (-0.16 %)
TLT $ 98.68 $ 0.78 (0.8 %)
GLD $ 232.46 $ 0.85 (0.37 %)
$ 23.6
$ 23.39
$ 23.59 x 100
$ 23.61 x 100
$ 22.99 - $ 23.76
$ 20.67 - $ 39.83
537,023
na
2.93B
$ 1.10
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 02-06-2024 12-31-2023 10-Q
4 11-29-2023 09-30-2023 10-K
5 08-07-2023 06-30-2023 10-Q
6 05-02-2023 03-31-2023 10-Q
7 02-06-2023 12-31-2022 10-Q
8 11-28-2022 09-30-2022 10-K
9 08-04-2022 06-30-2022 10-Q
10 05-10-2022 03-31-2022 10-Q
11 02-02-2022 12-31-2021 10-Q
12 11-22-2021 09-30-2021 10-K
13 08-05-2021 06-30-2021 10-Q
14 05-04-2021 03-31-2021 10-Q
15 02-04-2021 12-31-2020 10-Q
16 11-23-2020 09-30-2020 10-K
17 08-05-2020 06-30-2020 10-Q
18 05-07-2020 03-31-2020 10-Q
19 02-05-2020 12-31-2019 10-Q
20 11-25-2019 09-30-2019 10-K
21 08-05-2019 06-30-2019 10-Q
22 05-08-2019 03-31-2019 10-Q
23 02-07-2019 12-31-2018 10-Q
24 12-11-2018 09-30-2018 10-K
25 08-07-2018 06-30-2018 10-Q
26 05-08-2018 03-31-2018 10-Q
27 02-09-2018 12-31-2017 10-Q
28 12-12-2017 09-30-2017 10-K
29 08-03-2017 06-30-2017 10-Q
30 05-03-2017 03-31-2017 10-Q
31 02-06-2017 12-31-2016 10-Q
32 12-14-2016 09-30-2016 10-K
33 08-09-2016 06-30-2016 10-Q
34 05-10-2016 03-31-2016 10-Q
35 02-09-2016 12-31-2015 10-Q
36 12-14-2015 09-30-2015 10-K
37 08-04-2015 06-30-2015 10-Q
38 05-11-2015 03-31-2015 10-Q
39 02-09-2015 12-31-2014 10-Q
40 11-25-2014 09-30-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 arrowhead-pharmaceuticals-to-advance-two-new-rnai-based-obesity-candidates-aro-inhbe-and-aro-alk7-into-clinical-studies-after-they-demonstrated-the-potential-to-reduce-body-weight-and-fat-mass-with-a-novel-mechanism-of-action-that-may-lead-to-improved-preservation-of-lean-muscle-mass-compared-to-currently-approved-obesity-therapies

- Company hosting an obesity/metabolic R&D webinar today, August 14, 2024, at 2:00 pm ET as Part IV of the 2024 Summer Seri...

 b-riley-securities-reiterates-buy-on-arrowhead-pharma-maintains-55-price-target

B. Riley Securities analyst Mayank Mamtani reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $55 price target.

 arrowhead-pharmaceuticals-announces-500m-strategic-financing-facility

- Balance sheet strengthened with long-term, non-dilutive capital- $400 million funded at close with the potential to draw an a...

 arrowhead-pharma-q3-2024-gaap-eps-138-misses-053-estimate

Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(1.38) per share which missed the analyst consensus estimate of $(...

 hc-wainwright--co-reiterates-buy-on-arrowhead-pharma-maintains-60-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $60 pric...

 chardan-capital-maintains-buy-on-arrowhead-pharma-maintains-60-price-target

Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $60 price target.

 hc-wainwright--co-maintains-buy-on-arrowhead-pharma-lowers-price-target-to-60

HC Wainwright & Co. analyst Patrick Trucchio maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and lowers the price ta...

 chardan-capital-maintains-buy-on-arrowhead-pharma-maintains-60-price-target

Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $60 price target.

 arrowhead-pharmaceuticals-to-advance-investigational-plozasiran-into-phase-3-capitan-cardiovascular-outcomes-trial

– Based on results in the Phase 2 MUIR clinical study, the Phase 3 CAPITAN trial is designed to enroll patients with mixed hype...

 why-arrowhead-pharmaceuticals-arwr-stock-is-seeing-blue-skies

Arrowhead Pharmaceuticals shares are trading higher by more than 6% during Monday's session. The company announced that it ...

 arrowhead-pharmaceuticals-unveils-obesity-treatment-at-ada-conference

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based...

 5-biotech-stocks-with-key-catalysts-this-week-merck-intellia-verona-and-more

Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach.

 cantor-fitzgerald-reiterates-overweight-on-arrowhead-pharma

Cantor Fitzgerald analyst Alethia Young reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Overweight.

 hc-wainwright--co-reiterates-buy-on-arrowhead-pharma-maintains-90-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $90 pric...

 goldman-sachs-initiates-coverage-on-arrowhead-pharma-with-neutral-rating-announces-price-target-of-31

Goldman Sachs analyst Andrea Tan initiates coverage on Arrowhead Pharma (NASDAQ:ARWR) with a Neutral rating and announces Pr...

 why-is-arrowhead-pharmaceuticals-stock-trading-higher-on-monday

Arrowhead Pharmaceuticals announced Phase 3 PALISADE study results showing significant triglyceride reduction in familial chylo...

 hc-wainwright--co-reiterates-buy-on-arrowhead-pharma-maintains-90-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $90 pric...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION